Implantica AG Stock

Equities

IMP A SDB

SE0014855029

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 11:29:34 2024-05-31 am EDT 5-day change 1st Jan Change
29.85 SEK +5.29% Intraday chart for Implantica AG +5.11% +24.90%

Financials

Sales 2024 * 3.6M 3.9M 41.11M Sales 2025 * 10.35M 11.22M 118M Capitalization 740M 802M 8.45B
Net income 2024 * -36M -39.04M -411M Net income 2025 * -46M -49.89M -525M EV / Sales 2024 * 191 x
Net cash position 2024 * 50.95M 55.25M 582M Net cash position 2025 * 50.81M 55.1M 580M EV / Sales 2025 * 66.6 x
P/E ratio 2024 *
-4.14 x
P/E ratio 2025 *
-4.06 x
Employees 49
Yield 2024 *
-
Yield 2025 *
-
Free-Float 4.86%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Implantica AG, Q1 2024 Earnings Call, May 15, 2024
Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Implantica AG Announces the Eighth RefluxStop? Center of Excellence in Italy CI
Implantica's RefluxStop? Is Now Available in Seven Hospitals in Spain Adding Two New Centers of Excellence CI
Tranche Update on Implantica AG (OM:IMP A SDB)'s Equity Buyback Plan announced on April 6, 2023. CI
Implantica Submits Initial Module of US FDA Premarket Approval Application for GERD Medical Device MT
Implantica Submits U.S. FDA Premarket Approval Application for RefluxStop® (first module) CI
Implantica Completes Human Factors Validation Study for RefluxStop as Part of the US FDA Premarket Approval Process CI
Implantica to Deploy GERD Treatment in Spain MT
Implantica AG (publ.) Wins Another RefluxStop Public Tender in Europe with Hospital Universitario De Getafe CI
Implantica AG (OM:IMP A SDB) acquired IRCCS Saverio De Bellis. CI
Transcript : Implantica AG, Q4 2023 Earnings Call, Feb 16, 2024
Implantica AG Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Implantica Announces Completion of its First RefluxStop Procedures at Artemed Klinikum München Süd in Munich, Germany CI
Implantica Announces First Refluxstop Public Tender Win, Paving the Way for Permanent Reimbursement in Italy CI
More news
1 day+5.29%
1 week+5.11%
1 month+8.94%
3 months+6.99%
6 months+66.02%
Current year+24.90%
More quotes
1 week
27.95
Extreme 27.95
29.90
1 month
26.20
Extreme 26.2
29.90
Current year
23.80
Extreme 23.8
33.00
1 year
16.00
Extreme 16
33.00
3 years
15.40
Extreme 15.4
136.80
5 years
15.40
Extreme 15.4
178.90
10 years
15.40
Extreme 15.4
178.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 14-12-31
Director of Finance/CFO 46 19-12-31
Director/Board Member 67 19-12-31
Members of the board TitleAgeSince
Director/Board Member 69 19-12-31
Chairman 65 19-12-31
Director/Board Member 60 19-12-31
More insiders
Date Price Change Volume
24-05-31 29.85 +5.29% 45,591
24-05-30 28.35 -0.18% 25,680
24-05-29 28.4 -.--% 44,971
24-05-28 28.4 +0.35% 53,700
24-05-27 28.3 -0.35% 11,120

Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT

More quotes
Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.613 EUR
Average target price
3.834 EUR
Spread / Average Target
+46.73%
Consensus
  1. Stock Market
  2. Equities
  3. IMP A SDB Stock